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ORIGINAL ARTICLE
Introduction: MicroRNAs are small, noncoding RNAs that sup-
press gene expression by binding to the 3' untranslated region (UTR) 
and thereby repress translation or decrease messenger RNA stabil-
ity. Inhibitor of differentiation 1 (ID1) is a putative stem-cell gene 
involved in invasion and angiogenesis. We previously showed that 
ID1 is regulated by Src kinases, overexpressed in human lung adeno-
carcinoma, and targeted by Src-dependent microRNAs. The current 
study focused on the association between miR-381 and ID1 in lung 
adenocarcinoma.
Methods: An ID1 3'UTR-luciferase reporter assay was used to deter-
mine whether miR-381 directly targets ID1. Human lung cancer cell 
lines were stably transduced with a precursor of miR-381 to evaluate 
its role on ID1 expression and to investigate changes in cell migra-
tion and invasion. The Src tyrosine kinase inhibitors saracatinib and 
dasatinib were used to repress ID1 expression. MiR-381 expression 
was measured in 18 human lung adenocarcinomas and corresponding 
normal lung tissue by quantitative reverse-transcription polymerase 
chain reaction.
Results: ID1 is a direct target of miR-381 as shown by 3'UTR 
luciferase reporter assays. MiR-381 expression was negatively 
correlated with ID1 expression in lung cancer cell lines. Ectopic 
expression of miR-381 reduced ID1 mRNA and protein levels, and 
significantly decreased cell migration and invasion. Furthermore, 
miR-381 was significantly downregulated in human lung adenocar-
cinomas, and low miR-381 expression levels correlated with poor 
prognosis.
Conclusion: These results suggest that downregulation of miR-381 
and thus induction of its target ID1 may contribute to the metastatic 
potential of lung adenocarcinomas. Further studies to explore poten-
tial therapeutic strategies, including Src inhibitors, are ongoing.
Key Words: MiR-381, Inhibitor of differentiation protein 1, Src, 
Lung cancer.
(J Thorac Oncol. 2012;7: 1069–1077)
Lung cancer is the leading cause of cancer-related deaths in the world, and adenocarcinoma is the most frequent 
histopathologic type and can be further divided into several 
subtypes.1 More than 50% of lung adenocarcinomas carry 
driver-mutations in genes involved in the HER, ALK, RAS-
RAF-MEK, and PI3K-AKT pathways.2 This knowledge has 
paved the way for individualized molecular therapies, some 
of which have become standard-of-care, and others that are 
still experimental.3 Despite these major advances, lung adeno-
carcinomas remain difficult to treat, because they are highly 
aggressive and frequently recur even in very early stages.4 
To make further advances, it is essential to understand the 
molecular mechanisms driving the invasive potential of lung 
adenocarcinomas.
The Src family of nonreceptor protein tyrosine kinases 
contains nine members, including c-Src, Yes, Fyn, Lyn, Lck, 
Hck, Fgr, Blk, and Yrk. Src is part of the focal adhesion kinase 
complex, and mediates cell adhesion and migration.5 The Src 
signaling-pathway is also involved in angiogenesis, cell cycle 
control, and survival. Aberrant expression of activated Src 
was described in many types of cancer, including lung cancer.6 
Several Src inhibitors, including saracatinib and dasatinib, are 
currently investigated in clinical trials.7 We have previously 
shown that Src kinases (and Src inhibitors) regulate lung can-
cer cell migration and invasion through a molecular mecha-
nism that includes SMAD and Inhibitor of differentiation 1 
(ID1).8
ID1, together with the other family members ID2, 
ID3, and ID4, belongs to the helix-loop-helix protein 
superfamily, and acts as a dominant negative regulator of 
differentiation-specific basic helix-loop-helix transcription 
factors.9 ID proteins are essential proliferative factors for a 
large variety of cell types.10 The transforming growth factor-
β–related growth factors, including bone morphogenic 
proteins (BMPs) regulate ID family proteins through phos-
phorylation of Smad transcription factors.11 Furthermore, 
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ID1 is regulated by the interaction of Src tyrosine kinase 
signaling with the BMP-Smad pathway.8 ID1 plays a key 
role in tumor cell differentiation,12 proliferation,13 angio-
genesis,14–16 and metastasis.17,18
ID1 is frequently overexpressed in human can-
cer and associated with an aggressive tumor phenotype.19 
Repression of ID1 decreases growth of early tumors in ani-
mal models.15,20 All four members of the ID family are over-
expressed in small-cell lung cancer.21 We recently reported 
that ID1 protein levels were elevated in a case series of 
lung adenocarcinoma versus matched normal lung tissue, 
and that ID1 expression correlated with the expression of 
Src and MMP-9.22 These results have been confirmed in an 
additional study, where ID1 expression was an independent 
prognostic factor in patients with lung adenocarcinoma, 
regardless of tumor stage.23
Recently, microRNAs (miRNA) have been linked to the 
development and progression of cancer by regulating onco-
genes and tumor-suppressor genes.24,25 MiRNAs regulate gene 
expression at the post-transcriptional level through decreased 
translation, increased degradation of the target mRNA, or 
both.26,27 The miRNA-target interaction occurs through base 
pairing of the miRNA “seed region” (nucleotides 2–7) to the 
3′- untranslated region (UTR) of its cognate target mRNA.28 
Dysregulation of miRNA expression patterns was found in 
a variety of human diseases, including cancer.29 More than 
50% of miRNA genes are located within or near chromo-
somal fragile sites, common breakpoints, or minimal regions 
of loss-of-heterozygosity or amplification.30 In human can-
cers, including lung cancer, dysregulated miRNAs can act 
as oncogenes or tumor suppressors.31 Several groups showed 
that miRNA profiling is a reliable tool to distinguish between 
histological lung cancer subtypes.32,33 Furthermore, specific 
miRNA profiles have been evaluated to predict prognosis and 
disease recurrence in early-stage lung cancer.34,35 For example, 
let-7, which targets KRAS, was one of the first miRNAs with a 
prognostic role found dysregulated in lung cancer.36 The aims 
of the current study were to determine whether ID1 is a tar-
get of miRNA regulation, and to investigate the role of this 
mechanism in lung cancer cells.
MATERIALS AND METHODS
Selection of Candidate miRNAs and Target 
Recognition
Candidate miRNAs for binding to ID1 were identi-
fied using four web-based bioinformatic algorithms: Pictar37 
(http://pictar.mdc-berlin.de/), TargetScan28 (http://www.tar-
getscan.org/), MicroCosm Targets38 (http://www.ebi.ac.uk/
enright-srv/microcosm/htdocs/targets/v5/), and miRanda39 
(http://www.microrna.org/microrna/home.do). Target recog-
nition is based on complementarity of nucleotide sequence to 
the 3′-UTR region of ID1 mRNA.
Cell Lines and Reagents
The following cell lines were obtained from the 
American Type Culture Collection (ATCC, Manassas VA): 
A549, H460, and H1299. H820, HCC827, and HCC4011 
were provided by Dr. John Minna (UT Southwestern Medical 
Center, Dallas, TX). Cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma-Aldrich, Buchs, 
Switzerland) or in RPMI-1640 (Sigma-Aldrich) supple-
mented with 10% fetal bovine serum and antibiotic-anti-
mycotic solution (penicillin 100 U/ml, streptomycin sulfate 
100 µg/ml, amphotericin B 0.25 µg/ml; Sigma-Aldrich) 
at 37°C in a 5% CO
2
 humidified atmosphere. Saracatinib 
(AstraZeneca Pharmaceuticals, Macclesfield, United 
Kingdom) and dasatinib (LC Laboratories, Woburn MA) 
were solubilized in dimethyl sulfoxide to obtain a 10 mmol/l 
stock solution, which was stored at −20°C and freshly 
diluted in cell-culture medium for each experiment.
Clinical Samples
From a previous study of 61 non–small cell lung cancer 
cases and matched alveolar lung tissue,22 18 cases with a path-
ological diagnosis of lung adenocarcinoma and available tissue 
were included in the present study. All patients gave informed 
consent for retention and analysis of their tissue for research 
purposes and the institutional review board of our institute 
approved the tissue banking and the current project. From sur-
gical lobectomy specimen, biopsies were taken from six ran-
domly chosen sites of morphologically “normal lung” outside 
the macroscopic tumor area. For the correlation of miR-381 
expression levels in tumor and normal lung tissue, we used one 
tumor sample and one matched “normal” site from all the 18 
patients and measured expression of miR-381. RNA extraction 
from formalin-fixed and paraffin-embedded was performed as 
previously described40 using the miRNeasy mini Kit (Qiagen).
Luciferase Reporter Assays
H1299 cells were seeded in 96-well plates (30,000 
cells per well). After 24 hours, cells were transfected either 
with luciferase reporter plasmids containing a housekeeping 
gene 3′ UTR (Peptidylprolyl isomerase A) or ID1 3′UTR. 
(SwitchGear Genomics, Menlo Park, CA). These constructs 
were cotransfected with MISSION Human miRNA Mimics 
for miR-381 (Sigma-Aldrich) using Lipofectamine 2000 
(Invitrogen, Basel, Switzerland). Cells were lysed 24 hours 
after transfection and the activities of Firefly and Renilla 
luciferases were determined with a dual-luciferase assay sys-
tem (Promega). Values, normalized to housekeeping gene 
3′UTR transfected cells and relative to cells transfected with 
nontargeting control miRNA, are the means of three indepen-
dent experiments.
Quantitative RT-PCR
Total RNA was extracted using the miRNeasy mini kit 
and the RNase-free DNase Set to minimize risk of contami-
nation with genomic DNA, according to the manufacturer’s 
protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA 
of 1 to 2.5 µg was reverse transcribed using random primers 
and M-MLV Reverse Transcriptase (Promega AG, Dübendorf, 
Switzerland). For miRNA analysis, 1 µg RNA was reverse 
transcribed using the miScript Reverse Transcription Kit 
(Qiagen).
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Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed using iQ Sybr Green Supermix (Bio-Rad 
Laboratories AG, Reinach, Switzerland). Primer sequences for 
ID1 and 18S RNA have been published previously.8 MiR-381 
expression was assessed using the miScript SYBR Green PCR 
kit and the primer assay hsa-miR-381 (Qiagen). All measure-
ments were performed in duplicates, and the arithmetic mean 
of the comparative threshold cycle (Ct) values was used for 
calculations: Target gene mean Ct values were normalized to 
the mean Ct value of the respective housekeeping gene (18S 
RNA for mRNAs or SNORA-73A for miRNAs, respectively), 
mean Ct values (internal reference gene, ΔCt), and then to 
the experimental control (ΔΔCt). Obtained values were expo-
nentiated (2−ΔΔCt) to be expressed as n-fold changes in regu-
lation compared with the experimental control.41 Standard 
dilutions of cDNA (0.01 ng/µl up to 100 ng/µl, 10-fold steps) 
and melting curve analyses were performed to confirm accu-
racy. All qRT-PCR reactions were carried out on a 7900HT 
Fast Real-Time PCR system (Applied Biosystems, Rotkreuz, 
Switzerland).
Western Blot Analysis
Cells were lysed in lysis buffer (1% Triton X-100, 0.5% 
Nonidet NP-40, 1 mM ethylene glycol tetraacetic acid, 1 mM 
ethylenediaminetetraacetic acid, 150 mM NaCl, 10 mM Tris-
HCl) containing 1 mM Na
3
VO
4
, 10 mM NaF, 1 mM ZnCl
2
, 50 
µM Na
2
MoO
4
, and protease inhibitors (Complete Mini, Roche 
Diagnostics AG, Rotkreuz, Switzerland). Cell extracts were 
cleared by centrifugation. Total protein concentration was 
determined using Bradford quantification reagents (Bio-Rad 
Laboratories). Equal amounts of protein were electrophore-
sed on polyacrylamide gradient gels (4%–20%; Bio-Rad 
Laboratories). Separated proteins were transferred onto poly-
vinylidene fluoride membranes. Membranes were blocked for 
1 hour with tris-buffered saline 0.05%/Tween-20 containing 
5% milk powder, and incubated overnight with antibodies 
against ID1 (BioCheck, Inc., Foster City, CA) at 1:500. For 
loading control, β-Actin antibody (Millipore) at 1:104 was 
used. Horseradish-peroxidase–linked antimouse (at 1:1,000) 
and antirabbit (at 1:2,500) (Amersham, GE Healthcare Bio-
sciences, Uppsala, Sweden) secondary antibodies were used. 
Visualization was carried out by chemoluminescence (ECL 
detection, Amersham).
Lentivirus Preparation and Transduction
Lentiviral vectors expressing hsa-miR-381 precur-
sor or a scrambled control vector were purchased from 
System Biosciences (Mountain View, CA). pLKO1 lenti-
viral vectors expressing small hairpin (sh) RNAs targeting 
c-Src (NM 004383.x-835s1c1/TRCN0000000804 and NM 
004383.1-1648s1c1/TRCN0000199500) and a nontargeting 
short hairpin RNA control (SHCOO2) were purchased from 
Sigma-Aldrich. Lentivirus production and transduction was 
performed as described previously.42
Migration and Invasion Assays
A549 cells were seeded in a 6-well plate (2.5 × 105 cells/
well). After 24 hours, monolayers were scratched with a 2-ml 
pipette tip. Plates were washed three times with phosphate 
buffered saline. After 18 to 24 hours, cells were examined for 
resealing of the monolayer by light microscopy. Migration 
analysis was done by TScratch, a software tool developed to 
automatically analyze wound-healing assays. This software 
was developed by the Koumoutsakos group (CSE Lab), at the 
ETH Zürich.43 The cell-invasion assay was carried out using 
modified Boyden Chambers with mouse-matrigel–coated filter 
inserts with 8.0-µm pores in 24-well plates (Becton Dickinson 
AG, Allschwil, Switzerland). The detailed protocol was previ-
ously published.44 Briefly, A549 cells in 5% fetal bovine serum 
DMEM were seeded in the cell culture inserts. DMEM con-
taining 10% fetal bovine serum in the lower chamber served as 
the chemoattractant. After 24 hours, medium and cells in the 
cell-culture insert were removed, cells at the bottom side of the 
insert were formalin-fixed and stained with 0.5% methylene 
blue. Cell counting and photo-documentation were performed 
using a Leica DM IL microscop with a Leica DFC420C cam-
era and analysis with Leica Application Suite Version 2.7.1 
(Leica Microsystems AG, Heerbrugg, Switzerland).
Statistical Analysis
Experiments were performed at least three times. Values 
represent the mean of triplicate samples and SD of the mean. 
Differences in migration and invasion experiments were ana-
lyzed by t test. Differences in miR-381 expression between 
tumor and paired-matched normal tissue were compared by 
the nonparametric Wilcoxon signed ranked test. All other 
differences between groups were determined by the Mann-
Whitney U test. Correlation analysis of gene expression was 
done by Spearman correlation. The Kaplan-Meier method 
and log-rank tests were used to estimate event-free (EFS) 
and overall survival (OS) as a function of time. EFS and OS 
were calculated from the time of disease diagnosis. p Values 
were rated significant if < 0.05. The StatView software ver-
sion 5.0.1 (StatView, SAS Institute, Brüttisellen, Switzerland) 
and Analyse-it for Microsoft Excel version 2.24 (Analyse-it 
Software Ltd., Leeds, United Kingdom) were used for all 
calculations.
RESULTS
MiR-381 Binds to the ID1 3′UTR and Negatively 
Correlates with ID1 Expression
The four target recognition algorithms (Pictar, 
TargetScan, MicroCosm, miRanda) used to predict miRNA 
binding to the 3′UTR of ID1 identified 1, 37, 67, and 5 can-
didate miRNAs, respectively. Greater specificity in target 
prediction can be attained by using the consensus of multiple 
algorithms.45 The following miRNAs were predicted to bind 
the ID1 3′UTR by three of the four previously mentioned 
algorithms: miR-29a, miR-29b, miR-29c, and miR-381. Our 
data on the miR-29b family and its role in regulating ID1 and 
cell migration have been published recently.46
To demonstrate binding of the seed sequence of miR-
381 to the ID1 3′UTR, we used a 3′UTR luciferase reporter 
assay. The alignment of miR-381 with the ID1 3′UTR is illus-
trated (Fig. 1A). MiR-381 is predicted to bind nucleotides 324 
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to 330 of the ID1 3′UTR. H1299 cells were transfected with 
the miR-381 expression vector plus a luciferase construct con-
taining either the ID1 3′UTR or a housekeeping gene 3′UTR 
(peptidylprolyl isomerase A). The luminescence intensity 
was significantly decreased by transfection of the ID1 3′UTR 
(Fig. 1B). These results demonstrate that ID1 is a direct target 
of miR-381. In untreated lung cancer cell lines, basal miR-381 
levels were inversely associated with basal ID1 mRNA levels, 
independently of KRAS or endothelial growth factor recep-
tor mutation status. Using the Spearman correlation test for 
analysis, we found a significant negative correlation between 
miR-381 and ID1 mRNA expression in lung cancer cell lines 
(Fig. 1C).
Decreased ID1 Correlates with Upregulated 
miR-381 Expression Upon Src Inhibition
As previously reported, ID1 expression levels are depen-
dent on Src signaling.8 The cooperation of Src with the BMP-
Smad pathway is a strong regulator of ID1 transcription.8 In 
the current study, we used the Src inhibitors saracatinib and 
dasatinib to downregulate ID1, and showed a significant dose-
dependent increase of miR-381, up to threefold more than 
basal levels (Fig.2A and 2C). The dose-dependent downregu-
lation of p-Src and ID1 protein levels confirmed the activity of 
the Src inhibitors (Fig. 2, B and D).
Because saracatinib and dasatinib are dual Src/Abl 
inhibitors that can block additional members of the Src fam-
ily of kinases, we selectively inhibited c-Src using short 
hairpin RNA. The knockdown efficiency is demonstrated by 
downregulation of c-Src mRNA expression (Fig. 3A). The 
two- to threefold increase in miR-381 expression after the 
Src knockdown was comparable to the increase upon Src 
inhibitor incubation (Fig. 3B), clearly supporting the view 
that saracatinib and dasatinib upregulate miR-381 via Src 
inhibition.
We recently published a study showing that inhibi-
tion of ID1 through miR-29b significantly attenuates lung 
cancer cell migration and invasion.46 Therefore, we aimed 
to determine whether combining miR-29b and miR-381 
would have an additive effect on ID1 regulation and cell 
migration. The inhibition of ID1 mRNA by miR-381 or 
miR-29b alone or the miR-381/-29b transduction was 
not significantly different. Nevertheless, the inhibitory 
effect on A549 cell invasion was significantly greater (p = 
0.0006) with miR-381 than with miR-29b overexpression. 
Combining miR-29b and miR-381 did not further suppress 
migration of A549 cells.
MiR-381 is Downregulated in Lung 
Adenocarcinoma
We previously showed that Src and ID1 are coexpressed 
in human lung adenocarcinomas.22 To correlate these data 
with miR-381 levels, total RNA was extracted from 18 pri-
mary human lung adenocarcinomas. We found a strong nega-
tive correlation between miR-381 and ID1 expression levels 
(Spearman correlation: R = −0.6; p = 0.001).
To compare miRNA expression levels between lung 
cancer tissue and adjacent normal lung epithelium, we 
extracted RNA from morphologically normal lung tissue 
in the same 18 pa migration was confirmed in H1299 cells 
tients. In 15 of 18 (83%) analyzed adenocarcinoma samples, 
miR-381 was downregulated in tumor compared with normal 
lung tissue. Overall miR-381 expression was significantly 
lower in adenocarcinomas than in matched normal lung tis-
sue (Mann-Whitney U test, p = 0.003) (Fig. 4A). Using the 
median tumor level as the cutoff, tumor miR-381 expression 
FIGURE 1. MiR-381 targets the ID1 3′UTR and is reciprocally associated with ID1 expression. A, Sequence alignment of miR-
381 and its conserved target site in the ID1 3′UTR. B, Luciferase activity of the indicated construct cotransfected with miR-381 
mimics. The columns represent the means of three independent experiments. C, ID1 and miR-381 expression was detected by 
qRT-PCR. MiR-381 expression was normalized to SNORA-73A, ID1 expression was normalized to 18S RNA. Correlation between 
miR-381 and ID1 mRNA expression levels in lung cancer cell lines. Spearman correlation coefficient R = −0.91. ID1, inhibitor of 
differentiation 1; 3′UTR, 3′ untranslated region; qRT-PCR, quantitative real-time polymerase chain reaction.
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significantly correlated with EFS (p = 0.003) and OS (p = 0.02) 
(Fig. 4B and 4C). A statistical significant difference in tumor-
stage distribution between the two groups was excluded.
Ectopic Expression of miR-381 Represses ID1 
Levels and Inhibits Cell Migration/Invasion
Three lung adenocarcinoma cell lines (A549, H460, and 
H1299) were transduced with lentiviral vectors containing a 
precursor miR-381 or a scrambled control RNA. Transduction 
efficiency, measured by miR-381 qRT-PCR, was comparable 
in all three cell lines with a 2.5 to threefold increase of miR-
381 expression (Fig. 5A). Ectopic expression of miR-381 
suppressed ID1 mRNA and protein levels in all three cell 
lines (Fig. 5B and 5C). Using A549 cells, we found that ecto-
pic expression of miR-381 significantly reduced migration 
(open wound area 8% versus 26%; p = 0.004) and invasion 
FIGURE 2. MiR-381 expression correlates with ID1 repression. A, miR-381 expression was detected by qRT-PCR in three 
 different lung cancer cell lines (A549, H460, and H1299). Cells were incubated for 24 hours with saracatinib or with DMSO. 
The results were normalized to SNORA-73A expression and are shown as n-fold changes relative to the expression levels in cells 
incubated with DMSO. All data are representative of three independent experiments. * indicate p < 0.05 compared to DMSO 
incubated control cells. B, p-Src and ID1 protein levels were analyzed by Western blotting. Indicated cell lines were incubated 
for 24 hours with two different concentrations of saracatinib or DMSO as a control. β-actin was used as a loading control.  
C, miR-381 expression in lung cancer cell lines treated with two concentrations of dasatinib. Analysis as in (2A). D, p-Src and 
ID1 protein in lung cancer cell lines treated with two concentrations of dasatinib. Analysis as in (2B). ID1, inhibitor of differentia-
tion 1; DMSO, dimethyl sulfoxide; qRT-PCR, quantitative real-time polymerase chain reaction.
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FIGURE 3.  MiR-381 is directly regulated by c-Src. A, Confirmation of c-Src knockdown in three different lung cancer cell 
lines transduced with lentiviral vectors expressing shRNA targeting c-Src (sh c-Src) or a scramble control shRNA (control). c-Src 
expression was measured by qRT-PCR and normalized to 18S RNA. All data are representative of three independent experi-
ments. Differences in expression levels were analyzed by Mann-Whitney U test, *p < 0.05. B, miR-381 expression in c-Src 
knockdown and control lung cancer cell lines measured by qRT-PCR and normalized to SNORA-73A. All data are representative 
of three independent experiments. Statistical analysis as in (3A). qRT-PCR, Quantitative real-time polymerase chain reaction; 
shRNA, short hairpin RNA.
FIGURE 4. Significant repression of miR-381 in human adenocarcinoma is correlated with patient outcome. A, Tumor 
tissue from lung adenocarcinoma and matched lung tissue from 18 patients was collected, formalin fixed, and paraffin 
embedded. Total RNA was extracted as described and miR-381 levels were measured by qRT-PCR. Values are the differ-
ences in Ct values between miR-381 and the levels of the housekeeping small RNA SNORA-73A. Because a large Ct value 
corresponds to a low expression level, we reversed this relation by multiplying by (−1) for better readability. (4B and 4C), 
Kaplan-Meier curves for event-free survival (B) and overall survival (C) in 18 patients with lung adenocarcinoma, accord-
ing to tumor expression of miR-381 detected by qRT-PCR. Patients with miR-381 expression level more than the median 
expression of the whole cohort were classified as having high miR-381 level (gray line), all other patients were classified 
as having low miR-381 expression level (black line). Log-rank test was used for p values. qRT-PCR, quantitative real-time 
polymerase chain reaction.
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FIGURE 5. Ectopic expression of miR-381 downregulates ID1 levels and decreases migration/invasion. Cells were transduced 
with a lentiviral vector expressing precursor hsa-miR-381 or a scrambled vector (control). A, qRT-PCR for miR-381 to confirm the 
stable transduction of A549, H460, and H1299 cells with a lentiviral vector expressing precursor hsa-miR-381 or a scrambled 
control vector. All experiments were performed three times. *Mann-Whitney U test, p < 0.05. B, qRT-PCR for ID1 in A549, H460, 
and H1299 in control and miR-382 overexpressing cells. Results were normalized to 18S RNA and are shown as n-fold decrease 
relative to the level in the control cells. *Mann-Whitney U test, p < 0.05. C, Western blotting for total Src and ID1 in A549, 
H460, and H1299 cells. β-actin was used as loading control. D, Migration assay with A549 cells transduced with a scrambled 
vector (control), or a lentiviral vector containing hsa-miR-381 precursor (miR-381). Light microscopy images were performed 
immediately after scratching of the monolayer (0 hours), and 24 hours later. E, Invasion assay with A549 cells transduced with 
a control vector (control), or a lentiviral vector containing hsa-miR-381 precursor (miR-381). Cells were seeded onto matrigel 
chambers. After 24 hours, cells at the bottom of the insert were stained and counted. ID1, inhibitor of differentiation 1; qRT-
PCR, quantitative real-time polymerase chain reaction.
(p < 0.001) (Fig. 5D and 5E). The effect on cell migration was 
confirmed in H1299 cells (open wound area 15% versus 29%; 
p = 0.009) (Supplementary Figure, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A242)
DISCUSSION
The study by Ponz-Sarvise et al.23 suggested a prog-
nostic role for ID1 in patients with resected lung cancer. We 
showed that ID1 is frequently coexpressed with Src in human 
lung adenocarcinomas, and that ID1 is regulated by Src and 
implicated in lung cancer cell invasion.22 Growing evidence 
indicates that miRNAs are involved in cancer development 
and progression.47,48 In the current study, based on our previ-
ous work on Src and ID1, we used Src inhibitors to identify 
Src-dependent miRNAs binding to ID1 3′UTR. We identified 
miR-381 as a novel miRNA involved in the Src-ID1 pathway. 
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MiR-381 is encoded on the long arm of chromosome 14 and 
belongs to the miR-154 gene family. There is only scarce data 
about the role of mi-381 in tumorigenesis. Recently, miR-381 
together with miR-539 was associated with systemic mastocy-
tosis where both miRNAs are downregulated by the stem-cell 
factor and the KIT receptor. They repress the microphthalmia-
associated transcription factor by binding to the microphthal-
mia-associated transcription factor 3′UTR and thereby 
suppress malignant mast-cell proliferation.49 Moreover, miR-
381, miR-329, and miR-134 are involved in activity-depen-
dent dendritic outgrowth of hippocampal neurons.50
We observed a reciprocal association between miR-
381 and ID1 in lung cancer cell lines and primary adeno-
carcinomas. Our results also provide first evidence that 
miR-381 is involved in lung cancer cell migration and inva-
sion, and indicate that Src inhibitors dasatinib and saraca-
tinib may act through miRNAs. Dose-dependent regulation 
of miR-381 and ID1, and stable Src knockdown experi-
ments suggested that the effect of saracatinib and dasatinib 
on miR-381 was indeed Src-dependent. We speculate that 
miR-381 may act as a tumor suppressor in the lung, and 
that deregulation of miR-381 by Src may lead to activa-
tion of ID1.22 A recent study showed binding of miR-381 
to the 3′UTR of the glioma suppressor LRRC4. By regu-
lating LRRC4, miR-381 increased the in vitro and in vivo 
proliferation of glioma cells. In brain tumor tissue samples 
miR-381 was highly expressed compared to normal brain 
tissue, thus we postulate an oncogenic function for miR-381 
in glioma cells.51 This is in contrast to our findings in the 
lung, where low miR-381 levels are associated with tumor 
tissue. These findings may highlight the fact that miRNAs 
bind various mRNAs and their activity depends on the 
expression levels of their target mRNAs in the respective 
tissues. In brain tissue, for example, ID4 and not ID1 is the 
most highly expressed ID family member. ID4 participates 
in neural stem-cell differentiation, promotes angiogenesis 
and drives brain tumor genesis through notch signaling.52–54 
Interestingly, there is a putative miR-381 binding site in the 
ID4 3′UTR, and aberrant high miR-381 expression might 
contribute to early carcinogenesis in gliomas by targeting 
ID4. These differences in the expression of target mRNAs 
in various tissues might explain the different functions of 
miR-381 in lung compared to brain tissue.
Recently, a crosstalk between Src kinase and the 
Smad-ID1 pathway was described, which led to a new way 
to target ID1 with Src inhibitors, such as saracatinib or dasa-
tinib.8 These compounds are currently being tested in several 
clinical trials for solid tumors.7 Unfortunately, dasatinib has 
only shown modest activity as single agent in an unselected 
cohort of lung cancer patients.55 Therefore, predictive mark-
ers for better patient selection are needed for this particular 
treatment option. MiRNAs have been implicated in chemo- 
and radioresistance mechanisms of lung cancer56,57 and repre-
sent suitable biomarkers. We previously showed that ID1 and 
miR-29b are predictive for in vitro activity of saracatinib and 
dasatinib in lung cancer cell lines.46 Here we show that miR-
381 is regulated by Src inhibitors and is downregulated in 
human lung adenocarcinoma as well. We propose that miR-
381 could be added to the list of potential predictive markers 
for Src inhibition.
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